Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance
Journal of Thrombosis and Haemostasis · 2025-07 · 23 (7) · 2086-2094
DOI: 10.1016/j.jtha.2025.02.042 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-07. Verfasst von Barbara A Konkle und 13 weiteren Autor:innen. Beteiligte Einrichtung: Washington Center for Bleeding Disorders, Division of Hematology Oncology, University of Washington, Seattle, Washington, USA. Electronic address: ba…. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A, Genetic Therapy, Adrenal Cortex Hormones. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BioMarin Pharmaceutical Inc.
Abstract (Originalsprache)
Valoctocogene roxaparvovec is the only factor VIII (FVIII) gene therapy currently approved for adults with severe hemophilia A in Europe and the USA. Elevated alanine transaminase (transaminitis) has been the most common adverse event observed during valoctocogene roxaparvovec clinical trials. Typically mild and transient, this marker of hepatocyte injury coincides, in some patients, with reduced FVIII levels and is generally managed with a reactive course of corticosteroids. An essential step in optimizing outcomes for patients who receive valoctocogene roxaparvovec is reviewing the extensive evidence currently available on this topic to determine practices for managing transaminitis, if it occurs. This forum article provides practical guidance based on the available clinical data and expert opinion for evaluating and managing transaminitis with corticosteroids to mitigate potential declines in FVIII activity levels in adults with severe hemophilia A who have received valoctocogene roxaparvovec.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Washington Center for Bleeding Disorders, Division of Hematology Oncology, University of Washington, Seattle, Washington, USA. Electronic address: barbara.konkle@wacbd.org.
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Transplant…
- Hepatology, The Blizard Institute, Queen Mary University of London, London, UK.
- Haemostasis and Thrombosis Unit, Division of Adult Haematology, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
- Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
Förderung
- BioMarin Pharmaceutical Inc
Zitieren
APA
Konkle, B. A., Peyvandi, F., Foster, G. R., Hermans, C., La Mura, V., Leavitt, A. D., Lillicrap, D., Mahlangu, J., Ozelo, M. C., Pipe, S., Recht, M., Srivastava, A., Young, G., & Miesbach, W. (2025). Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. Journal of Thrombosis and Haemostasis, 23(7), 2086-2094. https://doi.org/10.1016/j.jtha.2025.02.042
Vancouver
Konkle BA, Peyvandi F, Foster GR, Hermans C, La Mura V, Leavitt AD, et al. Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. Journal of Thrombosis and Haemostasis. 2025;23(7):2086-2094. doi:10.1016/j.jtha.2025.02.042
BibTeX
@article{Konkle2025,
author = {Konkle, Barbara A and Peyvandi, Flora and Foster, Graham R and Hermans, Cedric and La Mura, Vincenzo and Leavitt, Andrew D and Lillicrap, David and Mahlangu, Johnny and Ozelo, Margareth C and Pipe, Steven and Recht, Michael and Srivastava, Alok and Young, Guy and Miesbach, Wolfgang},
title = {Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
volume = {23},
number = {7},
pages = {2086--2094},
doi = {10.1016/j.jtha.2025.02.042}
}
EUVIMED